echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Blood: Genetic-transcription analysis identifies key transcription factors as drivers of human leukemia

    Blood: Genetic-transcription analysis identifies key transcription factors as drivers of human leukemia

    • Last Update: 2020-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Acute erythritosa (AML-M6 or AEL) is a rare invasive blood malignant tumorPrevious studies have shown that AEL leukemia cells often carry complex nucleotypes and mutations of known AML-related cancer genesto better define the potential molecular mechanisms that drive red line phenotypes, the researchers studied 33 AEL samples representing three genetic subgroups of AEL, including TP53 mutations, epigenetic regulator mutations (such as DNMT3A, TET2, or IDH2), and cases of undefined low mutation loadsresearchers created a "space" based on transcriptionomics based on red lines vs myelin, in which most AEL samples showed different unique positioning than those of non-M6 AML and bone marrow hyperplasia syndrome, independent of the molecular subgroups mentioned aboveIt is worth noting that more than 25% of AEL patients , including genetically uncertain subgroups, showed abnormal expression of key transcription factors, including SKI, ERG, and ETO2The ectopic expression of these factors in the red precursor cells of mice hindered in vitro differentiation of the red line, leading to permanent biochemistry, which was associated with reduced chromatin accessibility of GATA1 binding sites and functional interference with GATA1 activityin vivo models show that the occurrence of deadly red, red/myelin-like hybrids, or other malignant tumors depends on the cell population that expresses a.daEL-related mutationsin summary, this study suggests that AEL is a molecular heterogeneous disease with red linehomogene, in part due to the abnormal activity of key red line transcription factors in hematopoietic stem cells or progenitor cells
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.